- Home
- VCEL vs PENN Comparison
VCEL vs PENN Comparison
Compare VCEL & PENN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VCEL | PENN |
|---|---|---|
| Founded | 1989 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 1997 | 1994 |
Fundamental Metrics
Financial Performance| Metric | VCEL | PENN |
|---|---|---|
| Price | $35.89 | $11.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 16 |
| Target Price | ★ $57.50 | $20.50 |
| AVG Volume (30 Days) | 417.8K | ★ 4.4M |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 236.54 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | $258,716,999.00 | ★ $6,823,800,000.00 |
| Revenue This Year | $18.02 | $7.19 |
| Revenue Next Year | $18.52 | $3.11 |
| P/E Ratio | $145.81 | ★ N/A |
| Revenue Growth | ★ 14.05 | 8.24 |
| 52 Week Low | $29.24 | $11.66 |
| 52 Week High | $58.77 | $23.08 |
Technical Indicators
Market Signals| Indicator | VCEL | PENN |
|---|---|---|
| Relative Strength Index (RSI) | 42.11 | 36.31 |
| Support Level | $33.30 | $12.19 |
| Resistance Level | $36.56 | $14.00 |
| Average True Range (ATR) | 1.56 | 0.68 |
| MACD | -0.27 | -0.06 |
| Stochastic Oscillator | 28.50 | 1.81 |
Price Performance
Historical ComparisonAbout VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
About PENN PENN Entertainment Inc.
Penn Entertainment's origins date back to its 1972 racetrack opening in Pennsylvania. Today, Penn operates 43 properties across 20 states and 12 brands, including Hollywood Casino and Ameristar. Land-based casinos represented 85% of total sales in 2024; 15% was from the interactive segment, which includes sports, iGaming, and media revenue. The retail portfolio generates mid-30s EBITDAR margins and helps position the company to obtain licenses for the digital wagering markets. Additionally, Penn's media asset, theScore, provides access to sports betting/iGaming technology and clientele, helping it form a leading digital position.